Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Business Wire
-- Collaboration to Leverage oNKo-innate’s Deep Expertise in NK Cell Tumor Biology to Discover Novel Therapies in Immuno-Oncology and Cell Therapy -- FOSTER CITY, Calif. & SANTA MONICA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200421005271/en/Current cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity, including checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play a critical surveillance and effector role in the immune system. NK cells
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence [Yahoo! Finance]Yahoo! Finance
- Madonna pens scathing post against Trump for 'unthinkable' decision to ignore World AIDS Day [FOX News]FOX News
- Mableton man uses TikTok to fight HIV stigma as federal government skips World AIDS Day recognition [CBS News]CBS News
- Elton John reveals what would make Trump one of the 'greatest presidents' in history [FOX News]FOX News
- National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- GILD's page on the SEC website